Section Arrow
MRNA.NASDAQ
- Moderna
Quotes are at least 15-min delayed:2024/10/31 19:32 EDT
Last
 54.36
-0.36 (-0.66%)
Day High 
54.575 
Prev. Close
54.72 
1-M High
67.5499 
Volume 
4.51M 
Bid
54
Ask
54.27
Day Low
52.92 
Open
54.35 
1-M Low
52.26 
Market Cap 
21.03B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 54.01 
20-SMA 56.25 
50-SMA 65.89 
52-W High 170.47 
52-W Low 52.26 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-15.35/-7.44
Enterprise Value
22.25B
Balance Sheet
Book Value Per Share
30.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.75B
Operating Revenue Per Share
7.11
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.